Kiadis Pharma B.V. develops new treatment options for end-stage cancer patients who may benefit from a bone marrow transplant.
The company’s lead product, ATIR™, is designed to expand the donor pool for end-stage blood cancer patients by significantly diminishing the risk of graft-versus-host disease in mismatched bone marrow transplants.
Portfolio: MedSciences Capital II B.V.
Current product development stage: phase II clinical trials. Listed on Euronext Amsterdam and Brussels